Nuclear factor kappa-light-chain-enhancer of activated B cells-regulated gene products (NF-κB-regulated gene products)

NF-κB-regulated gene products comprise a diverse group of proteins whose expression is transcriptionally controlled by the Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) family (Gilmore, 2006, 'NF-κB target genes'). These products include pro-inflammatory cytokines like TNF-α and IL-6, chemokines, and cell adhesion molecules (NCBI, 'The NF-kappaB Signaling Pathway'). They also encompass anti-apoptotic factors such as Bcl-2 and XIAP, which prevent programmed cell death (Nature Reviews Immunology, 2004). These proteins play a central role in the regulation of the immune response, inflammation, and cell survival. Dysregulation of these gene products is a hallmark of various pathologies, particularly chronic inflammatory diseases and many types of cancer (PubMed, PMC2858301). In cancer, the overproduction of these factors promotes tumor growth, survival, and resistance to chemotherapy. Therapeutic strategies often focus on inhibiting the NF-κB signaling pathway to suppress the production of these effectors (DrugBank, 'Bortezomib'). Alternatively, drugs may directly target the individual gene products, such as monoclonal antibodies against TNF-α. However, because NF-κB regulates a vast array of essential biological processes, broad inhibition can lead to significant safety concerns (StatPearls, 'NF-kappaB Inhibitors'). These concerns include severe immunosuppression and an increased risk of opportunistic infections.

Other names

NF-kappaB target gene productsNF-kappaB downstream effectorsNF-kappaB-dependent proteinsNF-kappaB-induced proteins

Inhibition of the NF-κB signaling pathway (e.g., via IKK complex inhibition or proteasome inhibition) to prevent the transcription of target genes, or direct antagonism of the specific protein products (Gilmore, 2006; DrugBank).